|
Cut Cost of Doing Business
| |
Join the SoCalBio Group Purchasing Program to enjoy significant savings on lab supplies and equipment from
For more info, call SoCalBio at
800-418-7079 ext 3
|
Join SoCalBio
Join SoCalBio leaders to promote the biotech and device industries in Los Angeles, Orange County and neighboring communities for job creation and overall economic growth.
|  |
| Thanks to SoCalBio Media Partners
|
|
|
|
July 26, 2013
|  Editor: Ahmed Enany
President & CEO
Southern California
Biomedical Council
enany@socalbio.org
www.socalbio.org
|
|
MARK YOUR CALENDAR
Featuring Next Gen. Medtech, Biotech & eHealth Companies To sponsor or make a business presentation, contact SoCalBio at |
|
New Funding
|
The Los Angeles-Based Meditope Biosciences Announces the Completion of a $3.6 Million Series A Round of Funding
 Meditope -- a spinoff of the City of Hope and alumnus of the 2012 SoCalBio Investor Conference -- has raised $3.6M in a Series A financing led by angel investors to advance its proprietary monoclonal antibody (mAb) linker technology platform. "We are grateful to have had the opportunity to be funded by angel investors, who include pioneers in the biotechnology industry and are supportive of our efforts to quickly advance the development of this exciting new technology platform into the clinic," said Stephanie Hsieh (photo right), the company's President & CEO and a leading member of the SoCalBio W3 Group ... Learn more about Meditope Biosciences
Second Sight Medical Products Files
to Raise $10.5 Million
 The Los Angeles-based medical device company is launching the Argus II. It is the first bionic eye that the FDA approved earlier this year. It was 20 years in the making. The device looks like a sunglass but incorporates a digital camera, which in turn communicates with an implant on the eye. It is aimed at patients suffering from late stage retinitis pigmentosa (RP) ... Read more
|
|
VC Investing
|
Who are the Most Active Venture Capital Firms in Healthcare?
 As investments in life science companies have dipped over the past few years, some investors have scaled back investments or walked away from the sector all together. But based on a tally by investment research firm PitchBook in its 2013 Venture Capital Healthcare Report, several firms have made 10 or more investments in pharmaceutical, medical device or health IT companies in the last year and a half ... Click here to access the list
Resources for Entrepreneurs:
|
|
CIRM
|
California Stem Cell Launches $70 Million Alpha Stem Cell Clinic Plan
Under the far-reaching proposal, which CIRM President Alan Trounson has been promoting for two years, the agency will finance five stem cell clinics at established institutions in California with grants of up to $11 million. Another $15 million will be allotted for a stem cell information and coordination center. Major matching contributions will be expected from award winners over the five-year terms of the grants ... Read more
|
|
Register for SoCalBio Events
|
SoCalBio Workforce Summit & Job Fair
(Notice New Date and Location)
Building the Bioeconomy Talent Pipeline
August 21, 2013, 8 am to 4 pm
Van de Kamp Innovation Center
2930 Fletcher Drive and San Fernando Road,
Los Angeles CA 90065
We are delighted to announce the following
Luncheon Keynote Speaker
Cathleen Benko
Vice Chairman & Chief Talent Officer
Deloitte
|
|
Sponsored Events
|
October 8 - 9, 2013 in San Francisco, CA
-----------------------------------------------------------------------------------------
November 11 - 13 in Beijing, China
|
|
Emerging Markets
|
China and Other Emerging Markets Question Drug Pricing by 60 Pharma Firms
International drugmakers are under fire in emerging markets as governments crack down on high prices and corporate malpractice, raising a risk to the price premiums global players enjoy over local rivals... Read more
|
|
Contract Dx
|
SoCalBio Member ResearchDx, the Leading Contract Diagnostics Organization, Completes Expansion Into a New Facility in Irvine
 ResearchDx, LLC of Irvine, California announced the purchase, build-out and relocation to a state of the art 30,000 sq. foot facility in Irvine California. The custom designed facility will support the firm's continued expansion of in vitro diagnostic (IVD) development services to the pharmaceutical, biotechnology, diagnostic development and clinical laboratory industries. .... Read more
|
|
Reverse Merger
|
The Los Angeles-Based Lion Biotechnologies Merges with Genesis Biopharma
 The merger will create a publicly traded biotechnology company, to be called Lion Biotechnologies, to be led by Manish Singh, PhD (photo right). The company is focused on developing T-cell based immunotherapy products for the treatment of cancer. Developed by Steven A. Rosenberg, chief of surgery at the National Cancer Institute (NCI), the company's core technology has demonstrated robust efficacy in Phase II clinical trials, indicating 50-72% response rates in Stage IV metastatic melanoma... Read more
|
|
C. Difficile Immunotherapy
|
Stellar Biotechnologies Announces Joint Research on Clostridium Difficile Immunotherapy
 The Port Hueneme-based Stellar and the University of Guelph in Australia are working together under research and license option arrangements forged last year around the two groups' shared interest in developing novel, non-antibiotic methods to treat the devastating C. diff infection... Read more
|
|
Hepetitis B
| |
The Pasadena-Based Arrowhead Research Commences Trials of Hep B Drug in Australia
 The Phase 1 trial is a single-center, randomized, double-blind, placebo-controlled, single dose-escalation, first-in-human study of ARC-520 administered intravenously to healthy adult volunteers and is being conducted in Melbourne, Australia. Each dose cohort includes 6 subjects randomized at ratio of 1:2 (placebo:active) to receive a single intravenous injection of either placebo or ARC-520. Arrowhead expects to complete this Phase 1 trial in the fourth quarter of 2013 and begin a Phase 2a trial in chronic HBV patients in 2014 ... Read more
|
|
Layoffs
| |
Abbott Slashes 200 More Jobs from Its
Temecula, Calif. Stent Campus
Abbott Laboratories is slashing another 200 positions from its Riverside County-based plant that produces cardiovascular stents and other devices, coming off the elimination of 450 jobs at the facility in February. The plant, along with the company's operations in French Valley, once employed about 4,000 people. That number is closer to 2,000 now ... Read more
|
| Join SoCalBio | |
Become a SoCalBio Member and Save Money by Utlizing the SoCalBio Group Purchasing Program
|
| Jobs Available | |
ResearchDx (Irvine)
Avita Medical (Northridge)
Aubrey Group (Irvine)
Second Sight Medical Products (Sylmar)
Alfred Mann Foundation for Scientific
Research (Santa Clarita)
C/A ARCHITECTS (Los Beach)
- Director of Infrastructure (The company is looking for a director who has an architectural or engineering background. Send resumes to: Brent Oswald)
WaveTec Vision (Aliso Viejo)
Response Genetics (Los Angeles)
Tribogenics (Marina del Rey)
Click to access more info
|
|
| About SoCalBio |
 SoCalBio membership links you to partners, contract manufacturers, regulatory and legal experts, and policy makers. The organization's programs help emerging biotech and medical device companies grow. Membership is affordable -- as low as $500 -- and offers access to networking opportunities, advocacy, discounts through our group purchasing program group purchasing program and other benefits you simply can't find elsewhere ... Join SoCalBio |
|
|
